Harvard–MIT Program in Health Sciences and Technology

EnPlusOne Biosciences to Attend and Present Poster at OTS Annual Meeting

Retrieved on: 
Friday, October 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Wyss Institute, Harvard–MIT Program in Health Sciences and Technology, MIT, OTS, Harvard Medical School, CSO, Manuscript, Engineering, Outline of health sciences, Therapy, Wyss Institute for Biologically Inspired Engineering, RNA, George Church, Doctor of Philosophy, Oligonucleotide, Enzyme, Harvard University, Poster, NTS Sessions 1–4, Wyss, Fine chemical

The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.

Key Points: 
  • The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.
  • The poster presentation is entitled “A Platform for Controlled Enzymatic Synthesis of RNA Oligonucleotides“ and will be delivered by Dominic Rainone, an Associate Scientist at EnPlusOne Biosciences, during Poster Session 1, which begins at 17:00 on October 23rd.
  • Additional technical data from this poster can also be found in EnPlusOne’s recent manuscript pre-print available online.
  • Likewise, we’ve been very strong supporters of OTS and its mission to bring the field of oligonucleotides to its full therapeutic potential.

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board

Retrieved on: 
Monday, October 23, 2023
American Cancer Society, Harvard–MIT Program in Health Sciences and Technology, Bachelor of Arts, Harvard Medical School, Brigham and Women's Hospital, IMGN, Genzyme, Biotechnology, ImmunoGen, MD, Drug, Harvard College, Senior, Medicine, Synageva, CBAB, ACS, LSE, Cancer, Hospital, BPMC, SAN, Management, Glycomimetic

SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).

Key Points: 
  • SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).
  • "We are pleased to welcome Dr. Goldberg as the 9th independent member of our CBAB," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
  • "Mark brings valuable clinical expertise in oncology, and his extensive biotechnology executive experience will be an asset to Anixa.
  • Dr. Goldberg received his Bachelor of Arts degree from Harvard College and his medical degree from the Harvard-MIT Program in Health Sciences and Technology.

Foresight Diagnostics Strengthens Leadership Team with Addition of Chief Business Officer John Truesdell

Retrieved on: 
Thursday, August 17, 2023
University of Colorado Boulder, United States Navy, University, Boston Scientific, NGS, Harvard–MIT Program in Health Sciences and Technology, Cancer, MIT Sloan School of Management, MBA, MS, MRD, Developmental Biology (journal), Patient, Standard of care, Outline of health sciences, Foresight, Foundation Medicine, Pharmaceutical industry, Management, Teleflex, Biochemistry

AURORA, Colo., Aug. 17, 2023 /PRNewswire/ -- Foresight Diagnostics, a leading provider of ultrasensitive cancer detection tests, today announced the appointment of John Truesdell as Chief Business Officer.

Key Points: 
  • AURORA, Colo., Aug. 17, 2023 /PRNewswire/ -- Foresight Diagnostics, a leading provider of ultrasensitive cancer detection tests, today announced the appointment of John Truesdell as Chief Business Officer.
  • John comes to Foresight most recently from SeQure Dx, where he served as Chief Business Officer.
  • "John's breadth of commercial leadership experience within this space make him an ideal addition to the Foresight Team," said Jake Chabon, CEO of Foresight Diagnostics.
  • "I am delighted to join Foresight Diagnostics as Chief Business Officer," said John Truesdell.

Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Wednesday, July 19, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Merit Cudkowicz, International, Harvard–MIT Program in Health Sciences and Technology, Life, Outline of health sciences, Clinical trial, American Academy, Boston, COYA, Forbes Norris, Harvard Medical School, National Institute of Neurological Disorders and Stroke, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, DSM-IV codes, Massachusetts Institute of Technology, Public health, Beth Israel Hospital, Patient, Coya, Chemical engineering, Master of Science, Hospital, American Academy of Neurology, Massachusetts General Hospital, Therapy, ALS, Harvard School of Dental Medicine, Commerce, Pharmaceutical industry, MD

Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.

Key Points: 
  • Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.
  • Dr. Cudkowicz brings decades of experience supporting the development of new therapies for ALS.
  • Dr. Cudkowicz has launched the first platform trial initiative in ALS, the HEALEY ALS Platform Trial, a program that helps accelerate therapy development in ALS.
  • Merit Cudkowicz commented: "I am happy to join Coya as a clinical advisor as they move COYA 302 into a well powered and designed clinical trial.

International Photodynamic Association: Global Experts Gather in Finland to Discuss Advances in Photomedicine – a Leading Alternative to Antibiotics in the Battle Against AMR

Retrieved on: 
Thursday, July 6, 2023
Medical Devices, Health, Health Technology, Research, Science, Biotechnology, Dentistry, Infection, Gold medal, Harvard–MIT Program in Health Sciences and Technology, University, PIT, PD, Life, World Congress, Sleep hygiene, PDT, PDD, Attention, AMR, Cutaneous leishmaniasis, Fungus, Doctor of Philosophy, Harvard Medical School, University of Coimbra, IPA, Congress, Hospital, Sinusitis, Patient, Outline of health sciences, Diagnosis, Fungal infection, Photodynamic therapy, Bacteria, HMS, Virus, Skin, Vaccine, Pharmaceutical industry, Dermatology, Chemistry

APDT has not only proven to be effective against all types of pathogens but does not generate resistance or serious adverse effects unlike antibiotics.

Key Points: 
  • APDT has not only proven to be effective against all types of pathogens but does not generate resistance or serious adverse effects unlike antibiotics.
  • There are a growing number of applications for aPDT that are being developed in leading research centres around the world.
  • It is gratifying to see the quality of research and commercial applications being showcased at this World Congress.
  • The Biennial International Photodynamic Association World Congress aims to bring together researchers and clinicians in all fields of Photodynamic Therapy (PDT) and Photodiagnosis (PDD) since 1986.

EnPlusOne Biosciences Expands Scientific Advisory Board

Retrieved on: 
Wednesday, February 8, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Gene editing, Middle States Commission on Higher Education, Wyss Institute, Defence Scientific Advisory Council, MIT, ALS, Young, Therapy, Dalhousie University, Harvard University, Harvard–MIT Program in Health Sciences and Technology, Biochemistry, Editorial, McGill University, Nucleic acid, Angel Award, RNA, George Church, United States Air Force Scientific Advisory Board, Harvard Medical School, Engineering, University, Wyss Institute for Biologically Inspired Engineering, Nucleic Acids Research, Oligonucleotide, Gene silencing, Outline of health sciences, Knowledge, OTS, Disease, Bachelor of Science, University of Massachusetts Chan Medical School, Angel, University of Massachusetts, Enzyme, Wyss, Doctor of Philosophy, Fine chemical, Management, Chemistry

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.
  • Dr. Watts, who was also a member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS) from 2015 to 2021, is a highly regarded scientific investigator in the oligonucleotide field.
  • Daniel Wiegand, MSChE, CEO of EnPlusOne said, “We are delighted to attract an experienced, respected researcher like Jon to our Scientific Advisory Board.
  • He serves on the Editorial Boards of Nucleic Acid Therapeutics and Nucleic Acids Research in addition to the Scientific Advisory Council of the OTS.

Random Math Wins 1st at Caltech-Harvey Mudd Math Competition, Sweeps Up Accolades at Berkeley Math Tournament

Retrieved on: 
Thursday, February 2, 2023
Attention, MIT, Stanford University, Harvard–MIT Program in Health Sciences and Technology, Harvard University, Student, Kavan, Multimedia, STEM, HMMT, Nursing, Tutoring, Management, California Institute of Technology, BMT

Furthermore, earlier this year, Random Math students have also found success in the Berkeley Math Tournament (BMT), held on Nov. 5.

Key Points: 
  • Furthermore, earlier this year, Random Math students have also found success in the Berkeley Math Tournament (BMT), held on Nov. 5.
  • The 1st place team, Saratoga 1, as well as the 8th place team Random Math, were both composed of the nearly the same set of students who represented Random Math at Caltech.
  • "We are extremely proud of our students and their accomplishments in this year's competitions," said Random Math cofounder, Manish Mishra.
  • Despite its colossal success on the national stage, Random Math remains a small program, containing just 250 students.

EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing

Retrieved on: 
Friday, September 30, 2022
Research, Venture Capital, Genetics, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Enzyme, Engineering, Therapy, Nucleotide, Outline of health sciences, RNA transfection, CFO, Woman, Wyss Institute, Silicon Valley Bank, Partner (business rank), MD, Asos, Research, CRISPR, MIT, CMO, Sirna Therapeutics, Harvard University, Biological engineering, Genetics, Technology, Vaccine, Laboratory, Solution, Doctor of Philosophy, Science, Wyss, George Church, Harvard–MIT Program in Health Sciences and Technology, Wyss Institute for Biologically Inspired Engineering, Harvard Medical School, RNA, Biotechnology, Silicon, Thermo Fisher Scientific, GMP, Innovation, Fine chemical, Management

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today formally launched with $12 million in seed financing.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today formally launched with $12 million in seed financing.
  • The financing will support continued development and scaling of the companys proprietary ezRNA synthesis platform in line with the companys mission to enable next-generation solutions for emerging RNA therapeutics.
  • EnPlusOne is pioneering an enzymatic-based RNA synthesis platform to address systemic issues inherent to existing chemical synthesis methods.
  • In addition to direct RNA synthesis, EnPlusOne's ezRNA platform supports a vast array of RNA solution applications.

CorVista Health Appoints Charles R. Bridges as Chief Scientific Officer

Retrieved on: 
Tuesday, January 18, 2022
Science, Cardiology, Radiology, Research, Pharmaceutical, Health, Fitness & Nutrition, Clinical Trials, Computer science, Applied physics, Patient, NIH, University, Mortality, Biological engineering, Exercise, FEC v. Wisconsin Right to Life, Inc., Electrical engineering, Harvard Medical School, Janssen Pharmaceuticals, National Institutes of Health, Degenerative disease, Injection, Â, Radiation, Department, Massachusetts Institute of Technology, Harvard–MIT Program in Health Sciences and Technology, University of North Carolina at Pembroke, View, Physics, Cardiovascular disease, Fasting, National, Circulatory system, Diagnosis, Harvard College, MD, Chemical engineering, Multimedia, Health care analytics, Pennsylvania Hospital, Professor, JNJ, Physician, Investment, Machine learning, Management, Medical device, Engineering, Science, Technology

CorVista Health, Inc., a digital health company dedicated to improving cardiovascular disease diagnosis, announces the appointment of Charles R. Bridges, M.D., Sc.D., as Executive Vice President and Chief Scientific Officer.

Key Points: 
  • CorVista Health, Inc., a digital health company dedicated to improving cardiovascular disease diagnosis, announces the appointment of Charles R. Bridges, M.D., Sc.D., as Executive Vice President and Chief Scientific Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220118005335/en/
    Dr. Charles Bridges, Chief Scientific Officer and Executive Vice President, CorVista Health.
  • His experience and vast clinical knowledge will be instrumental in getting our novel technology to market, said Don Crawford, President and Chief Executive Officer, CorVista Health.
  • I joined CorVista Health as I believe the CorVista System will be a revolutionary technology in aiding physicians to better diagnose cardiovascular disease, said Dr. Bridges.

Carpenter Technology Names Suniti Moudgil to the Position of Chief Technology Officer

Retrieved on: 
Monday, December 6, 2021
Carpenter Technology Corporation, Massachusetts Institute of Technology School of Engineering, NYSE, Electronics, Company, GLOBE, Alloy, Business, Research and development, Cobalt, Titanium, CEO, Nickel, Transport, R, AM, CRS, University, Chemical engineering, SSA Global Technologies, Massachusetts, Marketing, DuPont, Investment, Harvard–MIT Program in Health Sciences and Technology, Fine chemical

PHILADELPHIA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation(NYSE: CRS) today announced that Dr. Suniti Moudgil has joined the Company in the role of Chief Technology Officer, effective December 6, 2021.

Key Points: 
  • PHILADELPHIA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation(NYSE: CRS) today announced that Dr. Suniti Moudgil has joined the Company in the role of Chief Technology Officer, effective December 6, 2021.
  • As Chief Technology Officer, Dr. Moudgil will be responsible for leading the Companys technology strategy and Research & Development (R&D) organization, as well as overseeing the Companys intellectual property portfolio.
  • She then earned her Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, with a minor in Health Sciences and Technology.
  • Carpenter Technology has expanded its AM capabilities to provide a complete end-to-end solution to accelerate materials innovation and streamline parts production.